(Pre-)clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor.
about
Report on the use of non-clinical studies in the regulatory evaluation of oncology drugsTargeted therapy in advanced bladder cancer: what have we learned?Profile of pazopanib and its potential in the treatment of epithelial ovarian cancerCurrent classification, treatment options, and new perspectives in the management of adipocytic sarcomasPazopanib in the treatment of soft tissue sarcomaPazopanib, a new therapy for metastatic soft tissue sarcomaProspective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancerProgrammed death-ligand 1 expression is associated with fibrosarcomatous transformation of dermatofibrosarcoma protuberans.Successful use of pazopanib for treatment of refractory metastatic hemangiopericytoma.Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma: an EORTC-STBSG study.Pazopanib, a Receptor Tyrosine Kinase Inhibitor, Suppresses Tumor Growth through Angiogenesis in Dedifferentiated Liposarcoma Xenograft ModelsPazopanib exposure decreases as a result of an ifosfamide-dependent drug-drug interaction: results of a phase I studyUtility of vascular endothelial growth factor inhibitors in the treatment of ovarian cancer: from concept to application.Concise drug review: pazopanib and axitinib.Preoperative therapy with pazopanib in high-risk soft tissue sarcoma: a phase II window-of-opportunity study by the German Interdisciplinary Sarcoma Group (GISG-04/NOPASS).Angiogenesis-related pathways in the pathogenesis of ovarian cancerPhase II study of pazopanib monotherapy in metastatic gastroenteropancreatic neuroendocrine tumoursPazopanib, a novel multi-kinase inhibitor, shows potent antitumor activity in colon cancer through PUMA-mediated apoptosis.Pharmacokinetic evaluation of axitinib.New drugs in sarcomas.Pazopanib for the treatment of renal cell carcinoma.Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.Pazopanib in ovarian cancer.Clinical pharmacology, drug-drug interactions and safety of pazopanib: a review.The Role of PDGFs and PDGFRs in Colorectal Cancer.Pharmacokinetic drug evaluation of pazopanib for the treatment of uterine leiomyosarcomas.Pazopanib: a promising new agent in the treatment of soft tissue sarcomas.Dried blood spot analysis for therapeutic drug monitoring of pazopanib.Impact of pazopanib on docetaxel exposure: results of a phase I combination study with two different docetaxel schedules.Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE).Determination of pazopanib (GW-786034) in mouse plasma and brain tissue by liquid chromatography-tandem mass spectrometry (LC/MS-MS).Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization.Pazopanib for renal cell carcinoma leads to elevated mean arterial pressures in a murine model.Immunotherapeutic Targeting of Tumor-Associated Blood Vessels.An exploratory study investigating the metabolic activity and local cytokine profile in patients with melanoma treated with pazopanib and paclitaxel.Current Molecular Targeted Therapies for Bone and Soft Tissue Sarcomas.Value of FGFR2 expression for advanced gastric cancer patients receiving pazopanib plus CapeOX (capecitabine and oxaliplatin).The multi-kinase inhibitor pazopanib targets hepatic stellate cell activation and apoptosis alleviating progression of liver fibrosis.
P2860
Q26766039-E6368B08-D852-413B-92B2-E2BA6054A3EDQ27009469-226612A1-E21F-4CC2-8850-246DA8CB1D12Q27011840-14264DAA-56F3-4AB5-B1F3-E31E09617C92Q28076210-A4ACB4D4-4DA5-47D4-BE11-C4B2AA4936F7Q28269229-8D26421F-513B-4CF9-AF94-EFBEAE001A73Q28287163-A19C66B1-79E5-417F-9340-1369CD6010CCQ33430940-832AE03F-1B21-4E50-92FB-5E2DAFA40516Q33684256-A7D4AF58-4F5E-48D3-874A-EC32B3E3EED9Q34264348-6EE34C26-61ED-4BC0-802B-2653828D29FBQ34340390-08DCF623-FC58-4468-9999-7A8DCB1AA5BCQ35028802-37C1E8B2-1D6B-4EE7-960D-78EDA34560C7Q35074974-F4EE9ACD-4BE0-4505-80D9-EED6E12527D9Q35233993-6D736DE0-18A3-4AD3-A5B3-6D8F0D915EE1Q36182836-1D598405-11E8-4D17-AD8A-33BD24E5A9C9Q36472317-F074A023-090C-452E-8134-F6BB23002748Q37139109-8CA4BA4B-7978-497F-8E8A-FB80875CF441Q37182210-3D0E96EF-B34D-499E-9109-2F4BB6CB9896Q37709464-F646FA41-A133-418C-8A4A-F6CF0F246227Q37976135-E8A048CB-B780-4C7D-B881-31B0B619D931Q38165238-FA1D445C-E530-4720-8F9F-AEC4D55358ABQ38400468-10321770-BF50-4FC1-963F-DA3BEA3B8CE0Q38498207-400EBB6F-1F6C-4123-BA9D-5BC6B5F559D0Q38571120-A2CA69D8-32C0-4C9F-8350-6792646A3513Q38936104-CFCB8C7A-2F66-4234-BC4A-8040EB49BD56Q39120772-67A82AF0-3455-48BC-96DC-A7B595B34563Q39415429-B0B3518E-97B2-4D17-B1C1-A7484DDF5557Q39683594-E6CAF59D-A7B8-4F46-AA2E-B1669616BEB6Q40881271-68174DD4-A991-4D2F-8506-294E0A4325DDQ41658065-422A7ABD-66CB-4225-ABEA-BE3BD8AD1EBDQ41679292-313AB0B5-7B03-4905-AC16-5E7E1F3C64ADQ42236729-C087806C-E363-437E-A2AE-E37CC7FCE11BQ47131757-CA6A9070-32C2-4AD4-ADED-3869471BE263Q47367575-A5DFF3A1-6632-401C-9B23-6B332AE008F2Q49592831-206E5B7E-8F2A-4402-BF80-4C69C690DDB0Q51746622-902AA692-62BC-48CF-A853-404CC2283782Q52671439-6A61E7F4-F416-404D-8E7E-78FDF973DB54Q53167144-77EC06C6-D16B-4424-9AEB-263A0C2BDEAEQ53381128-FF793AFF-DA7D-4642-AC07-CB1F84ACA5F2
P2860
(Pre-)clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
(Pre-)clinical pharmacology an ...... kinase angiogenesis inhibitor.
@ast
(Pre-)clinical pharmacology an ...... kinase angiogenesis inhibitor.
@en
type
label
(Pre-)clinical pharmacology an ...... kinase angiogenesis inhibitor.
@ast
(Pre-)clinical pharmacology an ...... kinase angiogenesis inhibitor.
@en
prefLabel
(Pre-)clinical pharmacology an ...... kinase angiogenesis inhibitor.
@ast
(Pre-)clinical pharmacology an ...... kinase angiogenesis inhibitor.
@en
P2093
P2860
P1433
P1476
(Pre-)clinical pharmacology an ...... kinase angiogenesis inhibitor.
@en
P2093
Jaap Verweij
Paul Hamberg
Stefan Sleijfer
P2860
P304
P356
10.1634/THEONCOLOGIST.2009-0274
P577
2010-05-28T00:00:00Z